Study of Modified Atkins Diet in Kabuki Syndrome
Overview
Animal models of Kabuki syndrome have showed a reversal of the cognitive phenotype with ketogenic diet. Modified Atkins diet is safer and easier tolerated than full ketogenic diet and still has the histone deacetylase inhibition believed to be responsible for the cognitive improvement. This study aims to examine a small number of adults with Kabuki syndrome before and after 12 weeks on a modified Atkins diet to determine if there is any cognitive improvement and if the diet can be tolerated.
Full Title of Study: “Pilot Clinical Trial of Modified Atkins Diet for Kabuki Syndrome”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: April 2024
Detailed Description
Consented participants will participate in an initial 2 day study visit. These participants will undergo cognitive and neurobehavioral testing and also will have baseline labs drawn and will meet with a Johns Hopkins nutritionist trained in modified Atkins diet for education. The labs are standard of care for diet initiation to rule out contraindications to the diet. Participants and/or their caregivers will keep a daily diet log and will be asked to download the free Carb Manager application onto their smartphone. They will send the logs and data back weekly. Participants will be given urine ketone strips and asked to use and record in their diet log twice weekly. Participants will have blood and urine samples collected locally every 3 weeks and sent back to study team to measure Beta-hydroxybutyrate, metabolic studies and methylation. Participants will return to Baltimore at the end of 12 weeks for a one day visit to repeat the cognitive assessment protocol, neurobehavioral measures, and repeat the initial and follow up lab tests.
Interventions
- Dietary Supplement: Modified Atkins diet
- 12 weeks of modified Atkins diet
Arms, Groups and Cohorts
- Experimental: MAD diet group
- 15 adult participants with confirmed KMT2D pathogenic mutations. Baseline labs and education about Modified Atkins Diet. Then 12 weeks on a Modified Atkins Diet. Weekly urine dips for ketones and diet logs. Blood draw every 3 weeks.
Clinical Trial Outcome Measures
Primary Measures
- Benton Judgement of Line Orientation
- Time Frame: 12 weeks
- Established measure to determine visuospatial perception. There are 30 items and each item is worth 1 point. Will assess change in score from baseline to post-diet.
- Brief Visuospatial memory test
- Time Frame: 12 weeks
- Established measure to determine visuospatial memory. Scores range from 0 to 36 and a higher score indicates more correct responses. Will assess change in score from baseline to post-diet.
- NIH Toolbox Picture Sequence Memory
- Time Frame: 12 weeks
- Established measure to determine visuospatial memory. Scaled scores based on age have a mean of 100 and a standard deviation of 15 and higher scores indicate more correct responses. Will assess change in this score from baseline to post-diet.
- Beery Developmental Test of Visual Motor Integration
- Time Frame: 12 weeks
- Established measure to determine visuomotor integration. Scaled scores based on age have a mean of 100 and a standard deviation of 15 with a floor of 45 and higher scores indicate more correct responses. Will assess change in this score from baseline to post-diet.
- Beery Developmental Test of Visual Perception
- Time Frame: 12 weeks
- Established measure to determine visual perception. Scaled scores based on age have a mean of 100 and a standard deviation of 15 with a floor of 45 and higher scores indicate more correct responses. Will assess change in this score from baseline to post-diet.
- Wechsler Intelligence Scale for Children -V Block Design
- Time Frame: 12 weeks
- Established measure to determine visuospatial processing. Scaled scores which will be scaled to age 16:11 for all participants have a mean of 10 and a standard deviation of 1.5 with a range of 1-19 and higher scores indicate more correct responses. Will assess change in this score from baseline to post-diet.
- Hopkins Verbal Learning Test
- Time Frame: 12 weeks
- Established measure to determine verbal memory. Scores range from 0 to 36 and a higher score indicates more correct responses. Will assess change in score from baseline to post-diet.
Secondary Measures
- DNA Methylation analysis
- Time Frame: Every 3 weeks for 12 weeks
- Measure genome-wide methylation signature in blood of participants. To obtain genome-scale methylation measurements, bisulfite treated DNA from patient blood samples will be processed on the Infinium HumanMethylation450 BeadChip at the Johns Hopkins SNP Center in accordance with the manufacturer’s recommendation. The Infinium HumanMethylation450 BeadChip measures DNA methylation levels at 485,512 loci across the genome. The array data will then be analyzed to get the proportion of methylation at a given CpG site from 0 to 1. These will be logit transformed to create M-values. Kabuki syndrome is known to have a unique signature methylation profile (determined by M-values across loci) that can be detected in blood. This genome wide DNA methylation will be done every 3 weeks to determine whether this signature changes with dietary therapy.
- Caregiver behavior rating scales: GAS-ID
- Time Frame: 12 weeks
- Rating scale for anxiety consists of 27 items with scores ranging from 0-70 with higher scores indicating more anxiety. Performed at baseline and post-diet.
Participating in This Clinical Trial
Inclusion Criteria
We will recruit 15 total participants with clinically-definite and genetically-confirmed Kabuki syndrome type 1 age 18 years and older. . will also be required.
- Clinical diagnosis of KS will be made based on recently published consensus diagnosis criteria – Genetic confirmation of a pathogenic mutation in KMT2D Exclusion Criteria:
- presence of another known genetic syndrome – a health problem that would make a modified Atkins diet harmful – inability to travel to Baltimore for 2 visits separated by 12 weeks
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.